

Francois Bertucci

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2469783/francois-bertucci-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

113
papers

3,183
citations

32
h-index

54
g-index

131
ext. papers

4,262
ext. citations

7.8
avg, IF

5.18
L-index

#	Paper	IF	Citations
113	How basal are triple-negative breast cancers?. <i>International Journal of Cancer</i> , 2008 , 123, 236-40	7.5	336
112	Genomic characterization of metastatic breast cancers. <i>Nature</i> , 2019 , 569, 560-564	50.4	256
111	Integrated profiling of basal and luminal breast cancers. <i>Cancer Research</i> , 2007 , 67, 11565-75	10.1	232
110	Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. <i>PLoS ONE</i> , 2011 , 6, e27656	3.7	108
109	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. <i>Cancers</i> , 2019 , 11,	6.6	99
108	Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. <i>Clinical Cancer Research</i> , 2013 , 19, 4685-96	12.9	99
107	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. <i>Oncotarget</i> , 2017 , 6, e1253654	7.2	87
106	PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. <i>Oncotarget</i> , 2015 , 6, 13506-19	3.3	87
105	miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling. <i>Cell Reports</i> , 2017 , 18, 2256-2268	10.6	81
104	A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability. <i>Nature Medicine</i> , 2017 , 23, 568-578	50.5	78
103	Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. <i>Molecular Cancer</i> , 2014 , 13, 228	42.1	73
102	Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. <i>European Journal of Cancer</i> , 2016 , 58, 90-6	7.5	72
101	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. <i>Current Oncology Reports</i> , 2017 , 19, 64	6.3	71
100	Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. <i>European Journal of Cancer</i> , 2015 , 51, 742-50	7.5	70
99	Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. <i>Cell Metabolism</i> , 2021 , 33, 51-64.e9	24.6	57
98	PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. <i>Oncotarget</i> , 2017 , 6, e12781007.2	7.2	54
97	Comparative genomic analysis of primary tumors and metastases in breast cancer. <i>Oncotarget</i> , 2016 , 7, 27208-19	3.3	53

96	PDL1 expression is an independent prognostic factor in localized GIST. <i>Oncolmmunology</i> , 2015 , 4, e1002729	7.2	51
95	High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes. <i>PLoS ONE</i> , 2011 , 6, e16950	3.7	50
94	Defining the molecular biology of inflammatory breast cancer. <i>Seminars in Oncology</i> , 2008 , 35, 41-50	5.5	47
93	Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling. <i>PLoS ONE</i> , 2014 , 9, e81843	3.7	42
92	A 25-gene classifier predicts overall survival in resectable pancreatic cancer. <i>BMC Medicine</i> , 2017 , 15, 170	11.4	41
91	Genomic and expression analysis of microdissected inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 761-72	4.4	41
90	Genomic profiling of inflammatory breast cancer: a review. <i>Breast</i> , 2014 , 23, 538-45	3.6	40
89	Personalized medicine: present and future of breast cancer management. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 91, 223-33	7	40
88	Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. <i>Breast Cancer Research</i> , 2013 , 15, R112	8.3	39
87	PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. <i>European Journal of Cancer</i> , 2017 , 86, 28-36	7.5	35
86	Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. <i>Cancers</i> , 2019 , 11,	6.6	35
85	Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2016 , 17, 600-11	21.7	35
84	Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib. <i>PLoS ONE</i> , 2014 , 9, e104302	3.7	35
83	The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers. <i>Oncolmmunology</i> , 2016 , 5, e1085148	7.2	33
82	Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer. <i>Journal of Translational Medicine</i> , 2015 , 13, 138	8.5	32
81	PRICKLE1 Contributes to Cancer Cell Dissemination through Its Interaction with mTORC2. <i>Developmental Cell</i> , 2016 , 37, 311-325	10.2	32
80	ESPL1 is a candidate oncogene of luminal B breast cancers. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 51-9	4.4	31
79	Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. <i>Molecular Oncology</i> , 2015 , 9, 1218-33	7.9	30

78	EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. <i>Cancer Letters</i> , 2014 , 355, 70-5	9.9	30
77	Targeting Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. <i>Cancers</i> , 2018 , 10,	6.6	29
76	8q24 Cancer risk allele associated with major metastatic risk in inflammatory breast cancer. <i>PLoS ONE</i> , 2012 , 7, e37943	3.7	27
75	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response 2020 , 8,		23
74	The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1383-1391	8.7	23
73	Validation and comparison of the molecular classifications of pancreatic carcinomas. <i>Molecular Cancer</i> , 2017 , 16, 168	42.1	21
72	Pancreatic metastasis from osteosarcoma and Ewing sarcoma: literature review. <i>Scandinavian Journal of Gastroenterology</i> , 2013 , 48, 4-8	2.4	20
71	A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. <i>Cancers</i> , 2019 , 11,	6.6	17
70	expression is associated with longer postoperative, survival in adrenocortical carcinoma. <i>Oncolmmunology</i> , 2019 , 8, e1655362	7.2	16
69	Primary synovial sarcoma of the thyroid gland: case report and review of the literature. <i>Case Reports in Oncology</i> , 2014 , 7, 6-13	1	16
68	Sensitive and easy screening for circulating tumor cells by flow cytometry. <i>JCI Insight</i> , 2019 , 5,	9.9	16
67	Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC). <i>Neoplasia</i> , 2017 , 19, 564-573	6.4	15
66	PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?. <i>Cancers</i> , 2020 , 12,	6.6	15
65	New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?pi. <i>Cancers</i> , 2020 , 12,	6.6	15
64	PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target. <i>Molecular Oncology</i> , 2019 , 13, 1577-1588	7.9	14
63	Outpatient Cancer Care Delivery in the Context of E-Oncology: A French Perspective on "Cancer outside the Hospital Walls". <i>Cancers</i> , 2019 , 11,	6.6	14
62	The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype. <i>Npj Breast Cancer</i> , 2020 , 6, 8	7.8	14
61	Gene expression profiling of solitary fibrous tumors. <i>PLoS ONE</i> , 2013 , 8, e64497	3.7	13

60	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. <i>Molecular Oncology</i> , 2020 , 14, 504-519	7.9	13
59	Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. <i>Cancers</i> , 2019 , 11,	6.6	12
58	A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. <i>EMBO Molecular Medicine</i> , 2019 , 11, e9930	12	12
57	Inflammatory breast cancer cells are characterized by abrogated TGF β -dependent cell motility and SMAD3 activity. <i>Breast Cancer Research and Treatment</i> , 2020 , 180, 385-395	4.4	11
56	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6254-6265	12.9	10
55	Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	9
54	SPAG5: the ultimate marker of proliferation in early breast cancer?. <i>Lancet Oncology, The</i> , 2016 , 17, 863-865	8.7	9
53	Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. <i>European Journal of Cancer</i> , 2018 , 99, 28-36	7.5	9
52	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. <i>Genome Medicine</i> , 2021 , 13, 87	14.4	8
51	The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/ β Catenin Signaling. <i>Stem Cell Reports</i> , 2018 , 11, 1040-1050	8	8
50	Prognostic Value of Molecular Subtypes in Pancreatic Cancer. <i>Pancreas</i> , 2017 , 46, e29-e31	2.6	7
49	ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer. <i>British Journal of Cancer</i> , 2019 , 120, 931-940	8.7	7
48	Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.. <i>Cell Research</i> , 2022 ,	24.7	7
47	METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors. <i>Anticancer Research</i> , 2016 , 36, 293-9	2.3	7
46	Comprehensive genome characterization of solitary fibrous tumors using high-resolution array-based comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 2013 , 52, 156-64	5	6
45	Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer. <i>In Vivo</i> , 2020 , 34, 177-184	2.3	6
44	Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin. <i>Cancers</i> , 2019 , 11,	6.6	5
43	Gastrointestinal Stromal Tumour with Synchronous Bone Metastases: A Case Report and Literature Review. <i>Case Reports in Oncology</i> , 2017 , 10, 66-76	1	5

42	Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value. <i>International Journal of Molecular Sciences</i> , 2017 , 19,	6.3	5
41	Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?. <i>Cancers</i> , 2020 , 12,	6.6	5
40	"Wnt/ECatenin in GIST"-Letter. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 327-328	6.1	4
39	Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. <i>Clinical Epigenetics</i> , 2019 , 11, 141	7.7	4
38	PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 11507-11507	2.2	4
37	Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy. <i>Cancers</i> , 2021 , 13,	6.6	4
36	MARCKS protein overexpression is associated with poor prognosis in male breast cancer. <i>Cancer Biomarkers</i> , 2019 , 26, 513-522	3.8	4
35	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. <i>Onc Immunology</i> , 2021 , 10, 1929724	7.2	4
34	Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. <i>BMC Cancer</i> , 2020 , 20, 430	4.8	3
33	Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results. <i>Current Opinion in Oncology</i> , 2020 , 32, 585-593	4.2	3
32	A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 761-769.e2	4.3	3
31	Determinants of the access to remote specialised services provided by national sarcoma reference centres. <i>BMC Cancer</i> , 2021 , 21, 631	4.8	3
30	WEE1 Dependency and Pejorative Prognostic Value in Triple-Negative Breast Cancer. <i>Advanced Science</i> , 2021 , 8, e2101030	13.6	3
29	Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	3
28	Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 2314-2325	12.9	3
27	Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. <i>Molecular Oncology</i> , 2021 , 15, 2752-2765	7.9	3
26	Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma. <i>Cancer Genomics and Proteomics</i> , 2016 , 13, 191-200	3.3	3
25	Wnt Signaling Inhibition Promotes Apoptosis in Sarcomas-Letter. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 2324	6.1	2

24	Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	2
23	The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy. <i>Breast Cancer Research</i> , 2015 , 17, 54	8.3	2
22	High-grade soft tissue sarcoma arising in a desmoid tumor: case report and review of the literature. <i>Clinical Sarcoma Research</i> , 2015 , 5, 25	2.5	2
21	Difference in therapeutic response between basal and nonbasal triple-negative breast cancers. <i>Oncologist</i> , 2013 , 18, 1060-1	5.7	2
20	PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 575978	5.3	2
19	Ketogenic HMG-CoA lyase and its product β hydroxybutyrate promote pancreatic cancer progression.. <i>EMBO Journal</i> , 2022 , e110466	13	2
18	The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 593-606	3.5	1
17	A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers. <i>Cancers</i> , 2019 , 11,	6.6	1
16	BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells.. <i>Cell Death and Disease</i> , 2022 , 13, 96	9.8	1
15	Case Report: Grade 2 Metastatic Pancreatic Neuroendocrine Tumor With Progression of One Metastasis After Pregnancy to Grade 3 Large-Cell Neuroendocrine Carcinoma: One Case Cured by Resection With Genomic Characterization of the Two Components. <i>Frontiers in Oncology</i> , 2021 , 11, 646992	5.3	1
14	Antisense Oligonucleotide-Based Therapeutic against Menin for Triple-Negative Breast Cancer Treatment. <i>Biomedicines</i> , 2021 , 9,	4.8	1
13	Reversible rituximab-induced rectal Kaposi's sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma. <i>Clinical Sarcoma Research</i> , 2018 , 8, 11	2.5	1
12	Repeated Multimodality Ablative Therapies for Oligorecurrent Pulmonary Metastatic Disease.. <i>Current Oncology</i> , 2022 , 29, 1683-1694	2.8	1
11	A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer.. <i>Science China Life Sciences</i> , 2022 , 1	8.5	1
10	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.. <i>Npj Breast Cancer</i> , 2022 , 8, 12	7.8	0
9	TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. <i>European Journal of Cancer</i> , 2021 , 159, 205-214	7.5	0
8	The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 48	7.8	0
7	High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcS β pembrolizumab study from Unicancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 11520-11520	2.2	0

6	Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy. <i>Journal of Personalized Medicine</i> , 2022 , 12, 655	3.6	o
5	No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks Outcome?. <i>Cancers</i> , 2022 , 14, 2620	6.6	o
4	Successful Imatinib Treatment of an Abdominal Compartment Syndrome due to Huge Gastrointestinal Stromal Tumour. <i>Case Reports in Oncology</i> , 2019 , 12, 644-649	1	
3	Genomic landscape of inflammatory breast cancer identifies potential actionable genetic alterations. <i>Oncoscience</i> , 2020 , 7, 57-59	0.8	
2	Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer-Letter. <i>Clinical Cancer Research</i> , 2020 , 26, 5539	12.9	
1	Abstract P1-04-07: Xiap expression is associated with infiltration of cd163+ tumor-associated macrophages in the tumor micro-environment of inflammatory breast cancer. <i>Cancer Research</i> , 2022 , 82, P1-04-07-P1-04-07	10.1	